Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Oct;69(4):499–506. doi: 10.1136/jnnp.69.4.499

Evaluating the role of botulinum toxin in the management of focal hypertonia in adults

D Richardson 1, G Sheean 1, D Werring 1, M Desai 1, S Edwards 1, R Greenwood 1, A Thompson 1
PMCID: PMC1737149  PMID: 10990511

Abstract

OBJECTIVES—To investigate the effects of EMG guided botulinum toxin (BTX-A) on impairment and focal disability in adults presenting with focal hypertonia.
METHODS—A prospective, randomised, double blind, placebo controlled, parallel group trial was carried out with standardised assessment before and at 3 week intervals until 12 weeks after injection, in patients with focal hypertonia affecting upper or lower limbs. Botulinum toxin or placebo was injected with EMG guidance after multidisciplinary assessment. The modified Ashworth scale of spasticity, percentage passive range of joint motion, subjective rating of problem severity, the Rivermead motor assessment scale, a timed 10 metre walk (lower limb patients), nine hole peg test (upper limb patients), and a modified goal attainment scale were used as outcome measures. The patients were 52 adults; 34 male, 18female; mean age 40.31, range 16-79 years; mean duration of symptoms 35 months (range 3 months to 22 years). Diagnoses included cerebrovascular accidents (23), head injury (12), incomplete spinal cord injury (six), tumour (five), cerebral palsy (three), and anoxic episodes (three).
RESULTS—For each variable an overall score for the treatment period was computed by summing the scores from the 3, 6, 9, and 12 week assessments. These overall scores were significantly better in the treated group for the Ashworth scale, percentage passive range of movement, Rivermead lower limb, and subjective rating of problem severity. The significant treatment effect on the Ashworth scale was seen on analysis of variance (ANOVA) at 3 weeks and the subjective rating of problem severity at 3 and 6 weeks. The goal attainment scale score in both groups was similar at 12weeks.
CONCLUSION—Selective use of botulinum toxin to weaken muscles can lead to a reduction in resistance to passive movement about a distal limb joint. This allows for improvements in passive range of movement and focal disability, particularly in patients presenting with focal spasticity of the lower limb.



Full Text

The Full Text of this article is available as a PDF (147.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bohannon R. W., Smith M. B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987 Feb;67(2):206–207. doi: 10.1093/ptj/67.2.206. [DOI] [PubMed] [Google Scholar]
  2. Burbaud P., Wiart L., Dubos J. L., Gaujard E., Debelleix X., Joseph P. A., Mazaux J. M., Bioulac B., Barat M., Lagueny A. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):265–269. doi: 10.1136/jnnp.61.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cosgrove A. P., Corry I. S., Graham H. K. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol. 1994 May;36(5):386–396. doi: 10.1111/j.1469-8749.1994.tb11864.x. [DOI] [PubMed] [Google Scholar]
  4. Das T. K., Park D. M. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J. 1989 Apr;65(762):208–210. doi: 10.1136/pgmj.65.762.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dengler R., Neyer U., Wohlfarth K., Bettig U., Janzik H. H. Local botulinum toxin in the treatment of spastic drop foot. J Neurol. 1992 Aug;239(7):375–378. doi: 10.1007/BF00812153. [DOI] [PubMed] [Google Scholar]
  6. Dietz V., Quintern J., Berger W. Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia. Brain. 1981 Sep;104(3):431–449. doi: 10.1093/brain/104.3.431. [DOI] [PubMed] [Google Scholar]
  7. Dolly J. O., Black J., Williams R. S., Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature. 1984 Feb 2;307(5950):457–460. doi: 10.1038/307457a0. [DOI] [PubMed] [Google Scholar]
  8. Dunne J. W., Heye N., Dunne S. L. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):232–235. doi: 10.1136/jnnp.58.2.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hesse S., Krajnik J., Luecke D., Jahnke M. T., Gregoric M., Mauritz K. H. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke. 1996 Mar;27(3):455–460. doi: 10.1161/01.str.27.3.455. [DOI] [PubMed] [Google Scholar]
  10. Hesse S., Reiter F., Konrad M., Jahnke M. T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 1998 Oct;12(5):381–388. doi: 10.1191/026921598668275996. [DOI] [PubMed] [Google Scholar]
  11. Koman L. A., Mooney J. F., 3rd, Smith B. P., Goodman A., Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop. 1994 May-Jun;14(3):299–303. doi: 10.1097/01241398-199405000-00005. [DOI] [PubMed] [Google Scholar]
  12. Lincoln N., Leadbitter D. Assessment of motor function in stroke patients. Physiotherapy. 1979 Feb;65(2):48–51. [PubMed] [Google Scholar]
  13. Mathiowetz V., Weber K., Volland G., Kashman N. Reliability and validity of grip and pinch strength evaluations. J Hand Surg Am. 1984 Mar;9(2):222–226. doi: 10.1016/s0363-5023(84)80146-x. [DOI] [PubMed] [Google Scholar]
  14. O'Dwyer N. J., Ada L., Neilson P. D. Spasticity and muscle contracture following stroke. Brain. 1996 Oct;119(Pt 5):1737–1749. doi: 10.1093/brain/119.5.1737. [DOI] [PubMed] [Google Scholar]
  15. Simpson D. M., Alexander D. N., O'Brien C. F., Tagliati M., Aswad A. S., Leon J. M., Gibson J., Mordaunt J. M., Monaghan E. P. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996 May;46(5):1306–1310. doi: 10.1212/wnl.46.5.1306. [DOI] [PubMed] [Google Scholar]
  16. Yarkony G. M., Sahgal V. Contractures. A major complication of craniocerebral trauma. Clin Orthop Relat Res. 1987 Jun;(219):93–96. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES